Biohit Oyj - Company Announcement

The liquid handling business acquisition escrow account funds returned to Biohit Oyj

Biohit Oyj Stock Exchange Release April 1, 2014 at 4:00 pm local time (EET)



In connection with the sale of the liquid handling business in the end of year
2011, 10% of the sales price, EUR 6.8 million, was transferred to an escrow
account as collateral for any claims related to the sale. Biohit Oyj has
received the balance EUR 6.8 million in full on March 31, 2014, because no
claims related to deposit have been presented. Due to the terms and conditions
of the sale and other unresolved issues related to the transaction EUR 3.5
million of the capital gain from the sale was not recognised as income.
Operating profit for Q1 2014 from discontinued operations is estimated to show
some EUR 3.2 million as a remaining capital gain for the sale. The exact amount
will be specified in the interim report for Q1 2014. 



Additional information:

CEO Semi Korpela, Biohit Oyj
 tel. +358 9 773 861
 investor.relations@biohit.fi
 www.biohithealthcare.com


Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's
mission is “Innovating for Health” - we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare
group. www.biohithealthcare.com